Clinical Trial: A Phase 1 Study of VK2735 in Obese Adults Without Comorbidities

U.S., Sept. 25 -- ClinicalTrials.gov registry received information related to the study (NCT07838740) titled 'A Phase 1 Study of VK2735 in Obese Adults Without Comorbidities' on Sept. 09.

Brief Summary: The goal of this Phase 1, randomized, double-blind, placebo-controlled study is to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of VK2735 in adults who are obese (BMI >= 30 kg/m2) without comorbidities.

Study Start Date: Nov. 18, 2025

Study Type: INTERVENTIONAL

Condition: Obese Adults

Intervention: DRUG: VK2735 Drug

SC or oral once daily, once weekly, every other week, or monthly

DRUG: Placebo

SC or oral once daily or once weekly

Recruitment Status: RECRUITING

Sponsor: Viking Therapeutics, Inc.

Publi...